Equity Details
Price & Market Data
Price: $14.41
Daily Change: +$0.18 / 1.25%
Daily Range: $14.10 - $14.50
Market Cap: $878,784,512
Daily Volume: 665,449
Performance Metrics
1 Week: 0.56%
1 Month: -3.29%
3 Months: 9.75%
6 Months: -45.58%
1 Year: -44.70%
YTD: 4.42%
About Janux Therapeutics, Inc. (JANX)
A concise report on Janux Therapeutics, Inc. (JANX). Price: 14.41, daily change: +$0.18 / 1.25%. Market cap: 878,784,512. YTD performance and 1-month returns.
Company Details
Employees: 109
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.